David Goldfarb, MD
Nephrology · New York, NYNPI 1629018908
Payments from drug & device makers
Across 344 payments — averaging $2349.31 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Travere Therapeutics, Inc.$223K
- Akebia Therapeutics Inc$208K
- Novo Nordisk AS$197K
- Alnylam Pharmaceuticals Inc.$99K
- Novo Nordisk$22K
- Novo Nordisk US Research & Development, Inc.$19K
- plus $40K from 8 others
Across 2 payments — averaging $2000.00 each. Payments tied to a research study. These frequently flow through the physician to a hospital or research institution rather than to the physician personally.
- Novo Nordisk AS$4K
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Travere Therapeutics, Inc. | 17 | $222,771 |
| Akebia Therapeutics Inc | 147 | $208,159 |
| Novo Nordisk AS | 47 | $196,531 |
| Alnylam Pharmaceuticals Inc. | 46 | $99,311 |
| Novo Nordisk | 32 | $22,275 |
| Novo Nordisk US Research & Development, Inc. | 22 | $18,783 |
| Gilead | 1 | $13,765 |
| AstraZeneca | 23 | $13,646 |
| Sumitomo Pharma Co., Ltd. | 2 | $4,125 |
| Sanofi US Services Inc. | 1 | $2,855 |
| Novo Nordisk Health Care AG | 1 | $2,700 |
| Amgen | 2 | $2,629 |
| Eli Lilly | 1 | $500 |
| Vifor Pharma, Inc. | 2 | $111 |
How this compares
$808,162 in reported general payments places this provider in the 95th percentile of 935 nephrology providers in New York.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Other nephrology in New York
- Joji TokitaNew York$8.4M
- Krzysztof KirylukNew York$6.7M
- David BernardNew York$6M
- Andrew BombackNew York$3.4M
- Pietro CanettaNew York$3.2M
- Gerald AppelNew York$1.5M
- David CharytanNew York$1.3M
- Kirk CampbellNew York$1.1M
- Jai RadhakrishnanNew York$995K
- Girish NadkarniNew York$978K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.